VivoSeq
Infectious Disease

Dengue Fever

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Dengue Fever is an early-stage landscape with 0 programs across 3 companies. The most active players are Takeda, Novartis, Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

40/100

Attrition Rate

38/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 3Novartis logo

Novartis

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Completed2 · 25%
Withdrawn2 · 25%
Recruiting2 · 25%
Unknown status1 · 13%
Terminated1 · 13%

Clinical Trials

Trial Activity

8 trials

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
Recruiting·Novartis logoNovartis·Phase 2·NCT06006559·108 enrolled
A Randomized, Age-Descending, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Safety and Immunogenicity of 2 Doses of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Within the Routine Vaccination Schedule of Pediatric Participants ≥6 Months to <21 Months of Age
Recruiting·Takeda logoTakeda·Phase 3·NCT06665035·212 enrolled
Role of Andi-d in Dengue Fever: a Pilot Study
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT01443247·30 enrolled
Investigating Vector-borne Determinants of Aedes-transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT03534245·775 enrolled
A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever
Terminated·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT04906980·5 enrolled
IC14 in Adult Patients With Dengue Fever
Withdrawn·IImplicit Bioscience·Phase 2·NCT03875560
Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore
Withdrawn·SSingapore General Hospital·Phase 1/2·NCT02569827
Ketotifen as a Treatment for Vascular Leakage During Dengue Fever
Unknown status·NNational University Hospital, Singapore·Phase 4·NCT02673840·110 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)